# Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer

> **NCT00089102** · PHASE2 · TERMINATED · sponsor: **Medical University of South Carolina** · enrollment: 9 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00089102
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-09
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2018-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089102, "Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00089102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*